StreetAlpha.app
Home › Stocks › STOK

Stoke Therapeutics, Inc. (STOK)

Healthcare
$26.41
▼ −0.83%
LAST CLOSE · NOV 17

Stoke Therapeutics develops RNA-based medicines, led by zorevunersen, a candidate in clinical testing for Dravet syndrome, a severe genetic epilepsy. It last closed at $26.41 on Nov 17, down 0.83% on the day. In the past 30 days there were 1 dark pool print totaling $5.3M, the largest $5.3M.

AI Auto Pilots
Is STOK in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$28.2M
−86.3% vs a year ago
Net income
−$243.2M
−699.5% vs a year ago
EPS (diluted)
−$3.78
−655.9% vs a year ago
Free cash flow
−$215.7M
−764.7% margin
Valuation
Market cap
$1.7B
65.4M shares
P/E
–
No P/E while losing money
Price to sales
61.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$107.3M
At Sep 30
Shareholder equity
$352.6M
Shares outstanding
65.4M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $12.4M$12.4MFY2022FY2023: $8.8M$8.8MFY2023FY2024: $36.6M$36.6MFY2024FY2025: $184.4M$184.4MFY2025

From STOK's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated STOK in the past 90 days, not enough for a consensus
Average 12-month target
$40.00
▲ 51.5% upside

Based on 1 analyst who set a price target on STOK in the past 90 days. The average target is $40.00, with a high of $40.00 and a low of $40.00, compared with the last close of $26.41.

Low $40.00Avg $40.00High $40.00
Blue marker: last close $26.41
Highest target$40.00
Average target$40.00
Lowest target$40.00
Latest rating changes
JP MorganReinstated
Aug 21Buy$40
GuggenheimReiterated
Aug 4Buy$60
WedbushMaintained
Aug 4Buy$40
Canaccord GenuityMaintained
Aug 4Buy$58
Goldman SachsInitiated
Jul 13Buy$44
DateFirmActionRatingPrice target
Aug 21JP MorganReinstatedBuy$40
Aug 4GuggenheimReiteratedBuy$60
Aug 4WedbushMaintainedBuy$40
Aug 4Canaccord GenuityMaintainedBuy$58
Jul 13Goldman SachsInitiatedBuy$44
Loading…

Technical Analysis

STOK · as of the Nov 17 close · updated after every close
Moving sideways

The stock sits between its 20 and 50 day averages. It is 16% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 50). The nearest support is the 50 day average at $26.32, and the nearest resistance the 20 day average at $26.46.

Short trendNeutral
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 4.6%/day
Key levels
$40.2252 week high+52.3%
$30.75200 day average+16.4%
$28.72100 day average+8.7%
$26.98Pivot R1+2.2%
$26.69Swing high (Sep 30)+1.1%
$26.57Pivot+0.6%
$26.4620 day average+0.2%
$26.41Last close
$26.3250 day average−0.3%
$26.01Pivot S1−1.5%
$24.52Swing low (Oct 26)−7.2%
$22.0552 week low−16.5%
Indicators
RSI (14)49.69Middle of its rangeNeutral
MACD0.18Above its signal lineBullish
Stochastic35.8Middle of its rangeNeutral
ADX (14)16.1No clear trend
Williams %R-75.7Oversold below −80, overbought above −20Neutral
CCI (20)12.2Oversold below −100, overbought above 100Neutral
Rate of change−2.1%Change over 10 sessionsBearish
ATR (14)$1.21Typical daily range, 4.6% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Below
What happened before, for STOK

What happened before

See how STOK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow STOK usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How STOK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in STOK in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$5.3M
Largest print
$5.3M
Loading…

STOK Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼79 buying vs 101 selling
  • ▼Held by funds -5.7 pts
  • ▼Funds holding -13
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding185198−6.6%
In funds' top 1034−25.0%
Held by funds112.6%118.3%−5.7 pts
New / increased15 / 6428 / 76−24.0%
Reduced / sold out73 / 2857 / 28+18.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See STOK institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether STOK is in one of them and how their past STOK trades turned out.

STOK in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered STOK in an article yet. Here's the latest on the wider market.

About Stoke Therapeutics

Stoke Therapeutics is a biopharmaceutical company based in Bedford, Massachusetts, that develops RNA-based medicines. Its TANGO approach uses antisense oligonucleotides to raise levels of specific proteins in diseases caused by a shortage of one working gene copy. Its lead candidate, zorevunersen, is in late stage clinical testing for Dravet syndrome, a severe genetic epilepsy. The company focuses on diseases of the brain and eye and plans to sell its medicines to patients and healthcare providers in the United States, Canada and Mexico.

Headquarters
Bedford, MA